Kristina Casadei1, Carolyn Becker21Columbia University College of Physicians and Surgeons, New York, NY, USA; 2Brigham and Women’s Hospital, Division of Endocrinology, Diabetes, and Hypertension, Boston, MA, USAAbstract: Bisphosphonates are the mainstay of treatment for postmenopausal women with osteoporosis. Despite numerous clinical trials documenting efficacy, tolerability, and safety of bisphosphonate therapy, long-term persistence and adherence to these agents remains low. This has serious consequences for patients with osteoporosis in that medication non-compliance is associated with signifi cantly higher fracture risk. This review explores the unique physicochemical properties of bisphosphonates that allow more convenient i...
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk ...
Prevention of osteoporosis fractures is currently possible by implementing lifestyle changes as well...
BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment a...
María J Moro-Álvarez1, Manuel Díaz-Curiel21Hospital Central Cruz Roja, Madrid, ...
Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragil...
Bisphosphonates are the most widely prescribed drugs in osteoporosis today. They have unequivocally ...
Summary: This study showed that risedronate 150-mg once a month provides similar efficacy and safety...
This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. ...
Context Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Pa...
Background: Bisphosphonates have been effective in the treatment of osteoporosis and Paget\u27s dise...
Abstract: Risedronate is a third generation bisphosphonate used in the prevention of osteoporotic fr...
Osteoporosis has had a significant public health impact, with many sufferers experiencing fractures....
Summary: Bone mineral density response to once weekly delayed-release formulation of risedronate, gi...
Osteoporosis has had a significant public health impact, with many sufferers experiencing fractures....
Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 5...
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk ...
Prevention of osteoporosis fractures is currently possible by implementing lifestyle changes as well...
BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment a...
María J Moro-Álvarez1, Manuel Díaz-Curiel21Hospital Central Cruz Roja, Madrid, ...
Paula RackoffDivision of Rheumatology, Beth Israel Medical Center, New York, NY, USAAbstract: Fragil...
Bisphosphonates are the most widely prescribed drugs in osteoporosis today. They have unequivocally ...
Summary: This study showed that risedronate 150-mg once a month provides similar efficacy and safety...
This 2-year trial evaluated the efficacy and tolerability of a monthly oral regimen of risedronate. ...
Context Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Pa...
Background: Bisphosphonates have been effective in the treatment of osteoporosis and Paget\u27s dise...
Abstract: Risedronate is a third generation bisphosphonate used in the prevention of osteoporotic fr...
Osteoporosis has had a significant public health impact, with many sufferers experiencing fractures....
Summary: Bone mineral density response to once weekly delayed-release formulation of risedronate, gi...
Osteoporosis has had a significant public health impact, with many sufferers experiencing fractures....
Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 5...
UNLABELLED: Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk ...
Prevention of osteoporosis fractures is currently possible by implementing lifestyle changes as well...
BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment a...